Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
0.3625 SEK | -3.07% | -2.03% | -63.38% |
Apr. 24 | Episurf Medical Announces Distributor Agreement with Depuy-Synthes | CI |
Apr. 24 | Episurf Medical AB Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
Summary
- According to Refinitiv, the company's ESG score for its industry is poor.
Strengths
- The prospective high growth for the next fiscal years is among the main assets of the company
- For the last twelve months, analysts have been gradually revising upwards their EPS forecast for the upcoming fiscal year.
- For the past twelve months, EPS forecast has been revised upwards.
- The average target price set by analysts covering the stock is above current prices and offers a tremendous appreciation potential.
- Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.
Weaknesses
- As a percentage of sales and without taking into account depreciation and amortization, the company has relatively low margins.
- Low profitability weakens the company.
- One of the major weak points of the company is its financial situation.
- For the last twelve months, the trend in sales revisions has been clearly going down, which emphasizes downgraded expectations from the analysts.
- The sales outlook for the group was lowered in the last twelve months. This change in forecast points out a decline in activity as well as pessimistic analyses of the company.
- The average price target of analysts who are interested in the stock has been significantly revised downwards over the last four months.
- The group usually releases earnings worse than estimated.
Ratings chart - Surperformance
Chart ESG Refinitiv
Sector: Medical Equipment, Supplies & Distribution
1st Jan change | Capi. | Investor Rating | ESG Refinitiv | |
---|---|---|---|---|
-63.38% | 9.16M | D+ | ||
+13.16% | 129B | A- | ||
-9.49% | 10.77B | A- | ||
+3.60% | 9.05B | C | ||
+19.75% | 7.38B | C | ||
+22.28% | 4.88B | B+ | ||
+7.55% | 3.41B | C- | ||
-0.21% | 3.07B | B- | ||
-4.80% | 2.24B | - | - | |
-4.72% | 2.12B | - |
Financials
Valuation
Momentum
Consensus
Business Predictability
Environment
Governance
Controversy
Technical analysis
- Stock Market
- Equities
- EPIS B Stock
- Ratings Episurf Medical AB